Qkine manufactures high-purity, animal-free bioactive proteins and growth factors to support stem cell research and regenerative medicine.
Subscribe to see Qkine’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Qkine is a biotechnology company headquartered in United Kingdom, founded in 2016. Its most recent funding round, ch-sh01:MzUzNDg4OTkxMWFkaXF6a2N4, raised $1.1M in July 2026.
As of 16 November 2026. Source: Xcout Intel.
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| ch-sh01:MzUzNDg4OTkxMWFkaXF6a2N4 | $1.1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Qkine's closest competitors — see the full list of competitors and alternatives →
Established in 2010 and headquartered in Tokyo, Japan, Cyfuse Biomedical K.K. focuses on the creation, production, and distribution of regenerative medicine solutions. The company is actively involved in developing cell-based products for therapeutic regeneration, and it also undertakes contract work for cellular product research and development. Furthermore, Cyfuse Biomedical offers advanced Bio 3D Printers, which are instrumental in regenerating a variety of tissues and organs, including cartilage, bones, blood vessels, and nerves. Their specialized equipment includes 'regenova,' a bio 3D printer enabling three-dimensional cell stacking, and 'S-PIKE,' designed for forming complex 3D structures from cells.
Human Cell Design provides human cells and specialized services to accelerate and secure safe, clinically relevant scientific progress and pharmaceutical research.
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.
Bit Bio is a UK biotechnology company that develops technologies for precisely programming human cells, including its opti-ox platform for producing consistent, scalable cell types. It serves biomedical researchers, drug developers, and regenerative-medicine and cell-therapy developers with engineered human cells and related tools.
Cell Biologics, Inc. manufactures and sells primary cultured cells and cell culture products, including endothelial, epithelial, tumor, stem, and immune cells from human and various animal species. It also offers cell culture media, reagents, assay kits, custom cell isolation, and related research services such as adenoviral overexpression systems and next-generation sequencing library generation. The company serves life science researchers and is developing therapeutic platforms for inflammatory diseases and delivery systems for biologics.
Wuhan Healthgen Biotechnology Corp. develops and manufactures plant-derived recombinant human serum albumin and related biopharmaceutical materials. Its products serve biopharmaceutical manufacturers, including applications in cell culture, drug formulation, vaccines, and diagnostics.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Qkine? Suggest a correction · Work at Qkine? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.